IMR Press / FBE / Volume 2 / Issue 2 / DOI: 10.2741/E117

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis
Show Less
1 Clinical Research Programme, Stem Cells and Cancer Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

*Author to whom correspondence should be addressed.

 

Front. Biosci. (Elite Ed) 2010, 2(2), 602–613; https://doi.org/10.2741/E117
Published: 1 January 2010
Abstract

Over the past decade, increasing evidence suggested that stem cells play a crucial role not only in the generation of complex multicellular organisms, but also in the development and progression of malignant diseases. For the most abundant tumours, it has been shown that they contain a subset of distinct cancer cells that is exclusively responsible for tumour initiation and propagation These cells are termed cancer stem cells or tumour-initiating cells and they are also highly resistant to chemotherapeutic agents. Because CSC are preferentially endowed with the self-renewal capacity, it has further been hypothesized that they are also exclusively responsible for metastasis. Indeed, we were able to show that pancreatic caner stem cells contain a subpopulation of migrating cancer stem cells characterized by CXCR4 co-expression. Only these cells are capable of evading the primary tumour and metastasizing. Laboratories around the world are now aiming to further characterize these cells to eventually identify novel treatment modalities to fight cancer. Thus, cancer stem cells are promising new targets to counteract the growth-promoting and metastatic potential of solid tumours.

Keywords
CSCs
cancer stem cells
metastasis
CXCR4
tumourigenicity
malignancy
chemotherapy
Share
Back to top